Most of the writing about GLP-1s stops at the decision. Should you, shouldn’t you, here are the risks. Far less of it covers the part that actually takes up your life: you’ve decided, the prescription is real, and now you want to know what to expect and what’s yours to do. Starting a GLP-1 with PMOS (formerly PCOS) has a handful of practical steps that are easy to miss, and most of them happen before your first injection.
This is the companion piece to the risk breakdown. The numbers live there. This one is the timeline.
Want the questions written down before your appointment?
The GLP-1 Informed Consent Worksheet lays out the real numbers, the questions worth bringing to your prescriber, and what to actually watch for once you start. It’s exclusive to members of Shift Society, our community for women navigating PMOS (formerly PCOS) and metabolic health. Step 1: join. Step 2: open the GLP-1 lesson in the classroom and grab the worksheet from its resources.
In this article
What should you sort out before your first injection?
Four things, and they’re easier to handle now than to sort out later.
Confirm the hard stops don’t apply to you. There are two automatic no’s: a personal or family history of medullary thyroid cancer or MEN2, and pregnancy or breastfeeding. A third is a serious flag rather than an automatic no: a previous episode of NAION, a specific kind of vision loss, in one eye. Your prescriber will ask, but knowing your own family history before the appointment makes that conversation faster and more accurate.
Get current on your eye exams. A baseline before you start is a reasonable step, and it gives you and your care team something to compare against if anything changes later. If you already have diabetic eye changes, say so, because it changes how quickly anyone wants your blood sugar to move.
Tell every clinician you see, especially before a procedure. These medications slow how fast your stomach empties, which matters to a surgical or anaesthesia team. This one gets forgotten constantly because it doesn’t feel related. Put it on your medication list, not just in your memory.
If you’re on insulin, have the low blood sugar conversation first. That combination is where low blood sugar actually shows up, and the plan for it belongs in place before you need it, not after.
If you’re still weighing whether to start at all, that’s a different question with a different answer, and it’s covered in where GLP-1s fit in PCOS care, done ethically.
What do the first few weeks usually look like?
Mostly digestive, and mostly adjustable. Nausea and other gut symptoms are the ones people hear about first, and they’re often quite responsive to how the dose is handled. That’s a conversation with your prescriber, not something to push through quietly on your own.
One thing that’s less discussed: with these medications, faster is not better. Bringing blood sugar down very quickly carries its own eye risk, mostly for people who already have diabetic eye changes. A steady pace is a feature, not a delay.
The other change people report early is that food noise gets a lot quieter. That quiet is genuinely useful, and it’s worth naming what it’s for. It’s a window to build the foundations underneath, because the medication is holding something steady that you’re now free to work on. Where to actually start with blood sugar is a reasonable place to put that attention.
Which symptoms mean call your team the same day?
Three, and none of them are wait-and-see.
Persistent, severe abdominal pain, sometimes radiating to your back, with or without vomiting. That’s the pancreatitis picture. Most cases settle once the medication stops, but in the moment it needs to be looked at rather than waited out.
A sudden change in vision in one eye. Rare, and worth knowing the shape of, because NAION isn’t necessarily reversible.
New or worsening low mood. Worth watching during any significant change in your life, medication or not. The formal picture here has moved: the FDA in January 2024 and the EMA in April 2024 each reviewed the trial data, the cohort data and the adverse event reports, and neither found a proven cause and effect. The FDA has since asked for the warning to come off the label. Canadian labelling hasn’t caught up yet, so you may still see it on yours. Watching for it is still sensible. Reading it as an established risk is not what the reviews found.
The full numbers behind each of these, including what “doubles your risk” actually works out to in absolute terms, are in the companion risk breakdown: GLP-1 side effects, sorted into three buckets.
How do you protect muscle while you’re losing weight?
By treating it as part of the plan from the start rather than something to address if it becomes a problem.
Here’s why it matters more than it sounds. With any significant weight loss, some muscle comes off too. If the weight later comes back, the muscle doesn’t reliably come back with it. Repeat that cycle a few times and lean tissue drifts down while weight returns, which is a big part of why weight cycling costs more than it looks like it does.
Early research points at the obvious lever: people who paid attention to resistance training and getting enough protein came through with better body composition than people who didn’t. It’s a mitigable problem, not an inevitable one, and it’s more research-worthy than it currently is.
What that looks like in practice is a conversation with your own care team, who can factor in what your body is already doing and what you can realistically sustain.
What’s worth tracking between appointments?
Less than you’d think, and none of it is the scale alone.
The useful record is short: what changed, roughly when, and what happened after any dose adjustment. That’s it. Symptoms are data, not a report card, and a few honest notes make the next appointment far more productive than trying to reconstruct six weeks from memory.
It also changes the kind of appointment you get to have. Walking in with “the nausea eased about four days after the change, and my energy is better in the afternoons” gives your prescriber something to work with. Walking in with a number on a scale gives them much less.
What if the side effects aren’t worth it?
Then they aren’t worth it, and that’s a legitimate answer.
If something like nausea is still not tolerable after the dose has been adjusted, there’s no rule saying you have to continue. Other options exist. Stopping isn’t a failure of willpower or a wasted attempt, it’s informed consent working the way it’s supposed to, which includes the part where you get to change your mind with new information.
That’s the piece that gets lost in most of the coverage. Informed consent isn’t a form you sign once at the beginning. It’s an ongoing conversation, and your own values and preferences are a legitimate input into it the whole way through.
Watch the full video: Ozempic Side Effects: What’s Actually Reversible (And What’s Not).
Want to go deeper?
For the full step-by-step education, there’s the PCOS Pivot Course, and the PMOS Energy Code is a short challenge for the energy and fatigue piece.
In BC? A free Clarity Call is a short, no-pressure fit chat, not a medical visit.
This article is educational, not medical advice or a diagnosis. If something here resonates, bring it to your healthcare team, who can look at it through the lens of your individual health.
Main references
- Pasternak B, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024. PubMed
- Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024. PubMed
- Grauslund J, et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024. PubMed
- DeParis SW, et al. Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology. 2026. PubMed
- US Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications. Drug Safety Communication. FDA
